CASE REPORT

A 24 year-old male with no significant past medical history and no history of smoking was transferred to our facility for evaluation of refractory colitis. Four weeks prior to transfer, the patient underwent a dental bone graft procedure and was administered antibiotics to include amoxicillin and clindamycin. Within 1 week the patient developed watery diarrhea up to 10–12 times daily. The patient was initially administered a 5-day course of metronidazole empirically, and initial Clostridium difficile PCR toxin assay while on metronidazole returned negative. The patient had no improvement in clinical symptoms on metronidazole.

Two weeks prior to transfer, the patient was evaluated by a gastroenterologist and second C. difficile PCR toxin assay returned positive. Treatment was initiated with vancomycin without clinical improvement. The patient was subsequently admitted to an outside facility 1 week prior to transfer with a CT scan of the abdomen demonstrating pancolitis (Fig. 1).

INTRODUCTION

Ulcerative colitis (UC) is an idiopathic condition of the large intestine, in which inflammatory damage extends continuously from the rectum with variable extension to more proximal portions of the colon. Persistent inflammation and mucosal ulceration can lead to the recognized acute complications of UC including toxic megacolon, perforation and bleeding. Although genetic factors have demonstrated a role in the pathogenesis of UC, various environmental factors have been implicated in the rising incidence of UC. Enteric infections have been hypothesized to trigger an altered immune response leading to chronic inflammation. However, previous studies have also suggested a detection bias in the isolation of traditional enteric pathogens in IBD. Here we present the case of a newly diagnosed patient with UC presenting with multiple confounding enteric infections.

CASE REPORT

A 24 year-old male with no significant past medical history and no history of smoking was transferred to our facility for evaluation of refractory colitis. Four weeks prior to transfer, the patient underwent a dental bone graft procedure and was administered antibiotics to include amoxicillin and clindamycin. Within 1 week the patient developed watery diarrhea up to 10–12 times daily. The patient was initially administered a 5-day course of metronidazole empirically, and initial Clostridium difficile PCR toxin assay while on metronidazole returned negative. The patient had no improvement in clinical symptoms on metronidazole.

Two weeks prior to transfer, the patient was evaluated by a gastroenterologist and second C. difficile PCR toxin assay returned positive. Treatment was initiated with vancomycin without clinical improvement. The patient was subsequently admitted to an outside facility 1 week prior to transfer with a CT scan of the abdomen demonstrating pancolitis (Fig. 1).

Key Words: Inflammatory bowel diseases; Clostridium difficile; Colitis, ulcerative
The patient had no clinical improvement with oral vancomycin and intravenous metronidazole. He further described persistent abdominal pain, night sweats and a 11 kg weight loss.

On transfer to our facility, the patient had persistent bloody diarrhea. On physical examination the patient was afebrile and had diffuse abdominal discomfort. Initial laboratory studies revealed an elevated CRP, 41 mg/L, with a decreased albumin, 2.5 g/dL. Flexible sigmoidoscopy was performed demonstrating active colitis, without rectal sparing, and containing granular mucosa with a complete loss of vascular pattern (Fig. 2). Pathology revealed active colitis without changes of chronic colitis and without evidence for cytomegalovirus infection (Fig. 3). Stool culture on admission returned positive for *Klebsiella oxytoca* while repeat *C. difficile* PCR toxin assay following transfer was negative.

Given the presence of acute colitis and concern for antibiotic-associated hemorrhagic colitis secondary to *K. oxytoca*, antibiotics were withdrawn with clinical improvement in stool frequency. The patient was discharged with 1-week follow-up, at which time he continued to report symptoms of persistent colitis and weight loss. Repeat stool studies were performed to include a negative stool culture and positive *C. difficile* PCR toxin assay. Without formal diagnostic criteria present for UC, and in concern for recurrent *C. difficile* infection (CDI), the patient underwent a fecal microbiota transplantation (FMT) utilizing a third party source and instillation via colonoscopy, although no demonstrated clinical benefit was achieved. Colonoscopy at the time of FMT demonstrated persistent active colitis with a Mayo endoscopic

---

*Fig. 1.* Cross-sectional CT of the abdomen demonstrating diffuse inflammation and thickening of the colon wall (arrow).

*Fig. 2.* Endoscopic image demonstrating diffuse circumferential and continuous colitis with loss of vascular pattern, granular mucosa.

*Fig. 3.* Pathology demonstrating surface epithelial injury with neutrophilic cryptitis (inset), lamina propria infiltrate and crypt architectural distortion (H&E: A, ×4; B, ×20).
subscore of 2 extending from the anal verge to the cecum (Fig. 4). Biopsies revealed moderately active chronic colitis, now consistent with a diagnosis of UC.

Given lack of response to therapies for antibiotic-associated hemorrhagic colitis and CDI, and with biopsies now favoring UC 3 weeks after initial presentation, the patient was hospitalized due to persistent colitis, weight loss and abdominal discomfort. Therapy was initiated for severe UC to include intravenous corticosteroids and cyclosporine. The patient was discharged on oral tapering doses of prednisone and cyclosporine with transition to oral azathioprine. Subsequently, salvage therapies to include infliximab, vedolizumab and tofacitinib were trialed without clinical or endoscopic response despite targeting recommended drug levels resulting in the performance of a total colectomy fifteen months after initial presentation. Pathology from the colectomy specimen was consistent with severely active chronic colitis consistent with a final diagnosis of UC (Fig. 5). Informed consent was obtained from the patient for description of this case.

**DISCUSSION**

This is the first case report of *K. oxytoca* and *C. difficile* complicating a new diagnosis and management of UC. The role of enteric infections in the development of IBD has been postulated since the original disease descriptions, although a current accepted hypothesis is that commensal enteric bacteria provide constant antigenic stimulation to activate pathogenic T cells to cause chronic inflammation. As an altered microbial composition in IBD can result in increased immune stimulation and epithelial dysfunction, it is interesting to hypothesize the role of antibiotics triggering alterations in microbial composition. Recent studies in mouse models have demonstrated intergenerational transfer of antibiotic disturbances in the microbiota to the development of colitis in predisposed offspring. Extension of studies to the human demonstrated an increased risk of IBD among individuals exposed antibiotics, although exposure was only significant for the development of CD.

*K. oxytoca* is a Gram-negative cytoxin producing bacteria which has been previously described as the causative organism of antibiotic-associated hemorrhagic colitis, with only a single previous co-occurrence with *C. difficile*. In the initial report of 22 patients with antibiotic-associated colitis, 6 patients had findings on colonoscopy to include hemorrhagic colitis, of which 5 had isolated *K. oxytoca*. The primary associated antibiotics included penicillin derivatives and colonoscopy demonstrated a segmental colitis with rectal sparing. A subsequent case report associated *K. oxytoca* with the development of diffuse pseudomembranous colitis in the setting of perioperative antibiotic use and stool studies.
negative for alternative causes of pseudomembranous colitis to include cytomegalovirus, *Shigella dysenteriae*, *Escherichia coli* O157:H7. With withdrawal of empiric antibiotic therapy, diarrhea resolved within 4 days. A single case report has described *K. ocytoca* complicating a diagnosis of CD, while stool samples from 235 patients with IBD identified 11 (4.7%) harboring *K. ocytoca*, among which 2 strains were toxigenic.

This case report highlights the potential detection bias of enteric infections complicating a new diagnosis of UC. A study assessing the risks of *Salmonella* or *Campylobacter* isolation in stool culture demonstrated increased risks of both CD and UC following isolation of the enteric pathogens. However, risk of IBD was also increased with negative stool cultures, thus questioning the causality of the individual enteric infections and suggesting a detection bias related to increased testing for pathogens in IBD.

Although there is no evidence to support an etiologic role for CDI in IBD, it appears to be responsible for exacerbations of disease activity, leading to increased rates of hospitalization and colectomy. Early studies focused on the isolation of *C. difficile* toxin in the stool of relapsed patients demonstrating isolation rates of 4% to 19% in patients with symptomatic relapsed IBD. However, asymptomatic carriage of *C. difficile* has also been reported at an increased frequency compared to the general population with 8% of individuals with asymptomatic IBD carrying strains with a diversity pattern reflecting community acquisition.

Previously established reference standards for the diagnosis of CDI including cell cytotoxin assay and cytotoxigenic culture have been largely replaced with more cost-effective enzyme immunoassays and highly sensitive rapid PCR assays. However, changes in the test characteristics must be applied to clinical patient outcomes. In a recent study comparing PCR testing for toxin with molecular toxin immunoassays, individuals diagnosed with CDI by only PCR had shorter rates of diarrhea and no CDI-related complications, concluding that over-diagnosis leads to unnecessary treatment and increased health care costs.

This case report highlights the detection bias related to increased testing for stool pathogens in IBD as well as the potential etiologic role of microbiota disturbances in the development of IBD. While individual pathogens or antibiotics have not been demonstrated to be a causative factor in IBD, the shifts in the bacterial, fungal and viral environments in the intestinal track may play a role in the development of inflammation in genetically predisposed individuals. With the initial development of antibiotic-associated acute colitis in this case, strategies targeting enteric pathogens did not lead to resolution of clinical symptoms. Following the onset of chronic colitis demonstrated on histology, evidence-based strategies for UC were employed in an attempt to achieve clinical remission without benefit and leading to total colectomy. Therefore, this case highlights both the potential role of disturbances in the microbiota leading to the onset of IBD as well as the need for a high index of suspicion for underlying IBD among individuals presenting with enteric infections without previously identified risk factors, allowing for the prompt recognition and treatment of severe IBD.

**FINANCIAL SUPPORT**

The authors received no financial support for the research, authorship, and/or publication of this article.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**AUTHOR CONTRIBUTION**

Authorship guarantor: Dejan Micic, accepts full responsibility for the submitted work and description of the enclosed case including figures. Dejan Micic, Ayal Hirsch, and Namrata Setia: manuscript concept, drafting manuscript, preparation for submission. David T. Rubin: manuscript concept, drafting manuscript.

**REFERENCES**

1. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013;145:166-175.e8.
2. Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004;38:772-775.
3. Jess T, Simonsen J, Nielsen NM, et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut 2011;60:318-324.
4. Pola S, Patel D, Ramamoorthy S, et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:1315-1325.e4.
5. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-594.
6. Schuller AE, Battaglia T, Alvarez Y, et al. Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 2018;3:234-242.
7. Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 2014;109:1728-1738.
8. Högenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006;355:2418-2426.
9. Zollner-Schwetz I, Högenauer C, Joainig M, et al. Role of Klebsiella oxytoca in antibiotic-associated diarrhea. Clin Infect Dis 2008;47:e74-e78. doi: 10.1086/592074.
10. Sweetser S, Schroeder KW, Pardi DS. Pseudomembranous colitis secondary to Klebsiella oxytoca. Am J Gastroenterol 2009;104:2366-2368.
11. Plessier A, Cosnes J, Gendre JP, Beaugerie L. Intercurrent Klebsiella oxytoca colitis in a patient with Crohn’s disease. Gastroenterol Clin Biol 2002;26:799-800.
12. Zollner-Schwetz I, Herzog KA, Feierl G, et al. The toxin-producing pathobiont Klebsiella oxytoca is not associated with flares of inflammatory bowel diseases. Dig Dis Sci 2015;60:3393-3398.
13. Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2016;50:398-402.
14. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010;55:415-420.
15. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981;80:693-696.
16. Meyers S, Mayer L, Bottone E, Desmond E, Janowitz HD. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology 1981;80:697-670.
17. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009;104:1162-1169.
18. Dorman SA, Liggoria E, Winn WC Jr, Beeken WL. Isolation of Clostridium difficile from patients with inactive Crohn’s disease. Gastroenterology 1982;82:1348-1351.
19. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 2015;175:1792-1801.